Amundi’s Cogent Biosciences COGT Stock Holding History

Amundi’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$213K	Hold	5,515	–	–	﹤0.01%	1953
2026 Q1	$212K	Buy	+5,515	New	+$204K	﹤0.01%	1862
2025 Q2	–	Sell	-123	Closed	-$656	–	1770
2025 Q1	$656	Buy	123 +11	+10%	+$86	﹤0.01%	2102
2024 Q4	$908	Buy	+112	New	+$1.12K	﹤0.01%	2032

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Amundi's COGT Position: Q2 2026 in Review

Amundi held its Cogent Biosciences (COGT) position steady in Q2 2026 at 5,515 shares worth $213K. The position accounts for ﹤0.01% of the portfolio, ranked #1953.

Amundi first reported a position in COGT in Q4 2024 and has held it in 4 quarters since. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Amundi held 5,515 shares of Cogent Biosciences worth $213K as of Q2 2026.
Amundi left its Cogent Biosciences share count unchanged in Q2 2026.
Cogent Biosciences made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1953 holding.
Amundi first reported a position in Cogent Biosciences in Q4 2024 and has held it in 4 quarters since.
324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.